TY - JOUR T1 - Deoxyuridine Incorporation as a Useful Measure of Methotrexate and Metoprine Uptake and Metabolic Effectiveness JF - Molecular Pharmacology JO - Mol Pharmacol SP - 607 LP - 613 VL - 16 IS - 2 AU - W. DAVID SEDWICK AU - MARY JO FYFE AU - OLIVER E. BROWN AU - THOMAS A. FRAZER AU - MARC KUTLER AU - JOHN LASZLO Y1 - 1979/09/01 UR - http://molpharm.aspetjournals.org/content/16/2/607.abstract N2 - This paper contrasts the inhibition of deoxyuridine incorporation by the lipid-soluble antifolate, DDMP, and methotrexate in the human lymphoblastoid cell line, WIL-2. It shows how deoxyuridine incorporation can be used as an indirect tool for assay of drug uptake and facilitates interpretation of experiments with labeled drugs. Whereas 1 µM methotrexate takes 15-30 minutes to maximally inhibit deoxyuridine incorporation, DDMP maximally inhibits incorporation within five seconds of addition to the cell culture. These protocols expand the potential of deoxyuridine-based assays in analysis of antifolate action and may be useful for in vitro testing of potential tumor responses to antifolates. ER -